Ryman Healthcare Limited (NZE:RYM)
New Zealand
· Delayed Price · Currency is NZD | Market Cap | 2.20B |
| Revenue (ttm) | 807.48M |
| Net Income (ttm) | -564.03M |
| Shares Out | 1.01B |
| EPS (ttm) | -0.65 |
| PE Ratio | n/a |
| Forward PE | 18.24 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,398,879 |
| Average Volume | 1,498,799 |
| Open | 2.240 |
| Previous Close | 2.280 |
| Day's Range | 2.160 - 2.250 |
| 52-Week Range | 1.995 - 3.050 |
| Beta | 0.32 |
| RSI | 50.25 |
| Earnings Date | May 26, 2026 |
About Ryman Healthcare
Ryman Healthcare Limited develops, owns, and operates integrated retirement villages, rest homes, and hospitals for the older people in New Zealand and Australia. The company’s villages provide apartments and townhouses, and assisted-living in serviced apartments, as well as a care center, which offers rest homes, hospitals, specialist dementia care, and respite care services. Ryman Healthcare Limited was founded in 1984 and is based in Christchurch, New Zealand. [Read more]
Financial Performance
In fiscal year 2025, Ryman Healthcare's revenue was 759.16 million, an increase of 10.41% compared to the previous year's 687.56 million. Losses were -436.83 million, 157.5% more than in 2024.
Financial StatementsNews
Ryman Healthcare Transcript: Investor Day 2026
A refreshed strategy prioritizes sustainable recurring earnings, operational excellence, and disciplined capital management, targeting NZD 150 million in cash flow improvement and NZD 500 million in cash release by FY 2029. Portfolio optimization, product innovation, and a new dividend policy underpin long-term value creation.
Ryman Healthcare Earnings Call Transcript: H1 2026
Positive free cash flow and 13% revenue growth were achieved, with cost savings ahead of target and refinancing completed. Sales guidance was updated, margins moderated due to market conditions, and significant cash release opportunities remain in inventory and development assets.
Ryman Healthcare Transcript: AGM 2025
The AGM addressed significant financial losses, a major board and executive refresh, and a strategic reset focused on cash generation, cost reduction, and disciplined growth. Shareholders engaged robustly on development risks, capital management, and future dividends, with management emphasizing transparency and a path to recovery.
Ryman Healthcare Earnings Call Transcript: H2 2025
FY 2025 saw operational reset, improved free cash flow, and a strengthened balance sheet after a major equity raise. Sales and pricing were stable, with cost reductions underway and a focus on cash release from stock and land. Guidance points to improved performance in FY 2026.
Ryman Healthcare Earnings Call Transcript: H1 2025
Leadership transition and major accounting changes marked the period, with a net loss before tax and fair value movements, compressed margins, and negative free cash flow guidance as settlements are deferred. Cost savings and operational improvements are underway amid challenging market conditions.
Ryman Healthcare Transcript: AGM 2024
Revenue rose but profits fell sharply due to impairments and higher costs, prompting a focus on cash flow, capital discipline, and operational efficiency. Board renewal, auditor change, and sustainability initiatives were key themes, with dividends suspended and strategic reviews ongoing.